Perceptive Advisors’s Novavax NVAX Stock Holding History

Perceptive Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100,000	Closed	-$804K	–	100
2024 Q4	$804K	Hold	100,000	–	–	0.02%	91
2024 Q3	$1.26M	Hold	100,000	–	–	0.03%	99
2024 Q2	$1.27M	Sell	100,000 -600,000	-86%	-$6.04M	0.03%	98
2024 Q1	$3.35M	Sell	700,000 -700,000	-50%	-$3.25M	0.06%	99
2023 Q4	$4.75M	Buy	1,400,000 +100,000	+8%	+$612K	0.11%	78
2023 Q3	$3.77M	Buy	+1,300,000	New	+$10.4M	0.13%	75

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors's NVAX Position: Q1 2021 in Review

Perceptive Advisors sold out of Novavax (NVAX) in Q1 2021, closing a stake of 1,043,000 shares — an estimated $116M sold.

Perceptive Advisors first reported a position in NVAX in Q2 2016 and held it in 5 quarters. The position peaked at $116M in Q4 2020. 389 funds tracked by Wall St. Rank hold NVAX as of Q1 2021.

Perceptive Advisors reported no remaining Novavax position as of Q1 2021 after selling out during the quarter.
Perceptive Advisors sold 1,043,000 Novavax shares in Q1 2021, an estimated $116M.
Perceptive Advisors first reported a position in Novavax in Q2 2016 and held it in 5 quarters.
Perceptive Advisors's Novavax position peaked at $116M in Q4 2020.
389 funds tracked by Wall St. Rank held Novavax as of Q1 2021.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.